Study investigating new drug, IMC-1121B, in patients with advanced cancer of the stomach/oesophagus that has grown despite standard chemotherapy (combination of chemotherapy including platinum or fluoropyrimidine). Study has two arms. Patients will be assigned randomly to either arm: Arm1: 2/3 of patients receive IMC-1121B and best supportive care; Arm2: 1/3 receive an inactive substance (placebo) and best supportive care. Neither the patient nor the doctor will know the treatment arm.
- Conditions
- Metastatic Gastric CancerMedDRA version: 15.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2008-005964-15-MT
- Lead Sponsor
- ImClone LLC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 355
Each patient must meet the following criteria to be enrolled in this study.
1. Histologically- or cytologically-confirmed gastric carcinoma, including gastric adenocarcinoma or GEJ adenocarcinoma.
2. Metastatic disease or locally recurrent, unresectable disease with measurable lymph node metastases.
3. Measurable disease and/or evaluable disease. Measurable disease is defined as at least one unidimensionally-measurable target lesion (= 2 cm with conventional techniques or = 1 cm by spiral CT), as defined by RECIST. Examples of evaluable, nonmeasurable disease include gastric, peritoneal, or mesenteric thickening in areas of known disease, or peritoneal nodules that are too small to be considered measurable by RECIST.
4. Experienced disease progression during or within 4 months after the last dose of first-line therapy for metastatic disease, or during or within 6 months after the last dose of adjuvant therapy.
5. Disease is not amenable to potentially curative resection.
6. Patient is = 18 years of age.
7. Patient has a life expectancy of = 12 weeks.
8. Patient resolution to Grade = 1 (or to Grade = 2 in the case of neuropathy) by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0, of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia).
9. ECOG PS score of 0-1.
10. The patient has adequate hepatic function as defined by a total bilirubin = 1.5 mg/dL (25.65 µmol/L), and aspartate transaminase (AST) and alanine transaminase (ALT) = 3.0 x the upper limit of normal (ULN) [or 5.0 x the ULN in the setting of liver metastases].
11. The patient has adequate renal function as defined by a serum creatinine = 1.5 x the ULN, or creatinine clearance (measured via 24-hour urine collection) = 40 mL/minute (ie, if serum creatinine is > 1.5 x the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed).
12. The patient's urinary protein is = 1+ on dipstick or routine urinalysis ([UA]; if urine dipstick or routine analysis is = 2+, a 24-hour urine collection for protein must demonstrate < 1000 mg of protein in 24 hours to allow participation in the study).
13. The patient has adequate hematologic function, as evidenced by an absolute neutrophil count (ANC) = 1000/µL, hemoglobin = 9 g/dL (5.58 mmol/L), and platelets = 100,000/µL.
14. The patient must have adequate coagulation function as defined by International Normalized Ratio (INR) = 1.5 and a partial thromboplastin time (PTT) = 5 seconds above the ULN (unless receiving anticoagulation therapy). Patients on anticoagulation therapy with unresected primary tumors or local tumor recurrence following resection are not eligible.
15. If the patient has received prior anthracycline therapy as part of his or her first-line regimen, the patient is able to engage in ordinary physical activity without significant fatigue or dyspnea.
16. Because the teratogenicity of IMC-1121B is not known, the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods).
17. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization.
18. Able to provide informed written consent and is amenable to compliance with protocol schedules and testing.
Are the trial subjects under 18? no
Number of subjects for this age ran
Patients who meet any of the following criteria will be excluded from the study.
1. Documented and/or symptomatic brain or leptomeningeal metastases.
2. Experienced any Grade 3-4 gastrointestinal bleeding within 3 months prior to randomization.
3. Experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to randomization.
4. Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorders in the opinion of the investigator.
5. Ongoing or active psychiatric illness or social situation that would limit compliance with study requirements.
6. Uncontrolled or poorly-controlled hypertension despite standard medical management.
7. Patient has a serious or nonhealing wound, ulcer, or bone fracture.
8. Received chemotherapy, radiotherapy, immunotherapy, or targeted therapy for gastric cancer within 2 weeks prior to randomization.
9. Received any investigational therapy within 30 days prior to randomization.
10. Undergone major surgery within 28 days prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization.
11. Received prior therapy with an agent that directly inhibits VEGF or VEGFR-2 activity (including bevacizumab), or any antiangiogenic agent.
12. Receiving chronic antiplatelet therapy, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg/day) is permitted.
13. Patient has elective or planned major surgery to be performed during the course of the clinical trial.
14. Patient has a known allergy to any of the treatment components.
15. Pregnant or lactating.
16. Known to be positive for infection with the human immunodeficiency virus.
17. Known alcohol or drug dependency.
18. Patient has a concurrent active malignancy other than adequately-treated nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm. A patient with previous history of malignancy is eligible, provided that he/she has been free of disease for > 3 years.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method